A Phase 1 interventional study of Qishe Pill in Individuality and Narrative Medicine, sponsored by Shanghai University of Traditional Chinese Medicine. Status unknown at 1 site in China. Open to participants aged 20 Years to 35 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-11-19.
Sponsored by Shanghai University of Traditional Chinese Medicine · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Qishe Pill (Shanghai Sundise Traditional Chinese Medicine Co., Ltd, China), composed of processed Radix Astragali, Muscone, Szechuan Lovage Rhizome, Radix Stephaniae Tetrandrae, Ovientvine, and Calculus Bovis Artifactus, has been developed and spread in use into clinical settings in 2009. As individualization has become the trend of modern medicine, a personalized medicine of Qishe Pill should be documented and practiced with various patients according to the ancient TCM system, a classification of personalized constitution type, which has been established to determine predisposition and prognosis to diseases as well as therapy and life-style administration. Therefore, we describe the population pharmacokinetic profile of Qishe Pill and compare its extent of metabolism in the 3 major Constitution Type (Qi-Deficiency, Yin-Deficiency and Blood-Stasis) to address major challenges of individualized and standardized Traditional Chinese Medicine into clinical practice.
With the greatly increased morbidity of neck pain, it brought a large challenge to some optimal therapies for various situations in population at a given time based on their demographic, physiological and pathological characteristics. Chinese proprietary herbal medicines, as a kind of Complementary and Alternative Medicine (CAM), are usually developed from some well-established and long-standing recipes and formulated as tablets or capsules for commerce, convenience or palatability. Although these advantage mentioned, a good quantification and a strict standardization in detail are still need to be improved for individualized implementation in therapeutic strategies. Based on the YQHY decoction (Yi-Qi Hua-Yu Decoction, tonify Qi and promoting circulation and removing stasis), Qishe Pill (Shanghai Sundise Traditional Chinese Medicine Co., Ltd, China) has been developed and spread in use into clinical settings in 2009. As individualization has become the trend of modern medicine, a personalized medicine of Qishe Pill should be documented and practiced with various patients according to the ancient TCM system, a classification of personalized constitution type, which has been established to determine predisposition and prognosis to diseases as well as therapy and life-style administration. Therefore, we describe the population pharmacokinetic profile of Qishe Pill and compare its extent of metabolism in the 3 major Constitution Type (Qi-Deficiency, Yin-Deficiency and Blood-Stasis) to address major challenges of individualized and standardized Traditional Chinese Medicine into clinical practice.
20 studies on the registry are indexed under Narrative Medicine; 8 are open to participants now.
This study's planned enrollment of 36 is below the median of 60 across 12 interventional studies indexed under Narrative Medicine.
Browse Narrative Medicine studies →Shanghai University of Traditional Chinese Medicine is the lead sponsor of 102 studies on the registry; 20 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Qishe Pill(Shanghai Sundise Traditional Chinese Medicine Co., Ltd, China) in low dosage(3.75mg)
Drug: Qishe Pill
Qishe Pill(Shanghai Sundise Traditional Chinese Medicine Co., Ltd, China) in medial dosage(7.5mg)
Drug: Qishe Pill
Qishe Pill(Shanghai Sundise Traditional Chinese Medicine Co., Ltd, China)in high dosage(15mg)
Drug: Qishe Pill
Qishe Pill is a thin 0.15 g film-coated pill, composed of processed Radix Astragali, Muscone, Szechuan Lovage Rhizome, Radix Stephaniae Tetrandrae, Ovientvine, and Calculus Bovis Artifactus, which should be taken orally with water (240mL) after a minimum 10-hour fast
Plasma concentration of Qishe Pill
5 ml blood samples for pharmacokinetic analysis
Time frame: Dosing(0 hour)
Plasma concentration of Qishe Pill
5 ml blood samples for pharmacokinetic analysis
Time frame: 15 min after dosing
Plasma concentration of Qishe Pill
5 ml blood samples for pharmacokinetic analysis
Time frame: 30 min after dosing
Plasma concentration of Qishe Pill
5 ml blood samples for pharmacokinetic analysis
Time frame: 45 min after dosing
Plasma concentration of Qishe Pill
5 ml blood samples for pharmacokinetic analysis
Time frame: 60 min after dosing
Plasma concentration of Qishe Pill
5 ml blood samples for pharmacokinetic analysis
Time frame: 90 min after dosing
Plasma concentration of Qishe Pill
5 ml blood samples for pharmacokinetic analysis
Time frame: 120 min after dosing
Plasma concentration of Qishe Pill
5 ml blood samples for pharmacokinetic analysis
Time frame: 150 min after dosing
Plasma concentration of Qishe Pill
5 ml blood samples for pharmacokinetic analysis
Time frame: 180 min after dosing
Plasma concentration of Qishe Pill
5 ml blood samples for pharmacokinetic analysis
Time frame: 240 min after dosing
Plasma concentration of Qishe Pill
5 ml blood samples for pharmacokinetic analysis
Time frame: 360 min after dosing
Plasma concentration of Qishe Pill
5 ml blood samples for pharmacokinetic analysis
Time frame: 480 min after dosing
Plasma concentration of Qishe Pill
5 ml blood samples for pharmacokinetic analysis
Time frame: 600 min after dosing
Plasma concentration of Qishe Pill
5 ml blood samples for pharmacokinetic analysis
Time frame: 720 min after dosing
Plasma concentrations of Qishe Pill
5 ml blood samples for pharmacokinetic analysis
Time frame: 1440 min after dosing
Plasma concentration of Qishe Pill
5 ml blood samples for pharmacokinetic analysis
Time frame: 2160 min after dosing
Plasma sampling of Qishe Pill for pharmacokinetic analysis
5 ml blood samples for pharmacokinetic analysis
Time frame: 2880 min after dosing
Vital signs
body temperature, heart rate and blood pressure
Time frame: Dosing(0 hour)
Vital signs
body temperature, heart rate and blood pressure
Time frame: 180 min after dosing
Vital signs
body temperature, heart rate and blood pressure
Time frame: 720 min after dosing
Vital signs
body temperature, heart rate and blood pressure
Time frame: 1440 min after dosing
Vital signs
body temperature, heart rate and blood pressure
Time frame: 2160 min after dosing
Vital signs
body temperature, heart rate and blood pressure
Time frame: 2880 min after dosing
ECG monitoring
Electrocardiograms (ECGs)
Time frame: Dosing(0 hour)
ECG monitoring
Electrocardiograms (ECGs)
Time frame: 180 min after dosing
ECG monitoring
Electrocardiograms (ECGs)
Time frame: 720 min after dosing
ECG monitoring
Electrocardiograms (ECGs)
Time frame: 1440 min after dosing
ECG monitoring
Electrocardiograms (ECGs)
Time frame: 2160 min after dosing
ECG monitoring
Electrocardiograms (ECGs)
Time frame: 2880 min after dosing
Number of Participants with Adverse Events
The investigators will assess all clinical AEs according to the Medical Dictionary for Regular Activities criteria, in terms of intensity (mild, moderate, or severe), duration, outcome and relationship to the study drug.
Time frame: Day 1 of drug administration and blood sampling
Number of Participants with Adverse Events
The investigators will assess all clinical AEs according to the Medical Dictionary for Regular Activities criteria, in terms of intensity (mild, moderate, or severe), duration, outcome and relationship to the study drug.
Time frame: Day 2 of drug administration and blood sampling
Number of Participants with Adverse Events
The investigators will assess all clinical AEs according to the Medical Dictionary for Regular Activities criteria, in terms of intensity (mild, moderate, or severe), duration, outcome and relationship to the study drug.
Time frame: Day 3 of drug administration and blood sampling
Number of Participants with Adverse Events
Subjects will be requested to return to the study unit 4 d after drug administration and blood sampling for a follow-up visit.
Time frame: 4 days after drug administration and blood sampling
Peak Plasma Concentration (Cmax) of Qishe Pill in low dosage
The maximum plasma concentration
Time frame: 4 days after drug administration and blood sampling
Peak Plasma Concentration (Cmax) of Qishe Pill in medial dosage
The maximum plasma concentration
Time frame: 4 days after drug administration and blood sampling
Peak Plasma Concentration (Cmax) of Qishe Pill in high dosage
The maximum plasma concentration
Time frame: 4 days after drug administration and blood sampling
The Time to Peak Plasma Concentration (Tmax) of Qishe Pill in low dosage
The time to maximum concentration
Time frame: 4 days after drug administration and blood sampling
The Time to Peak Plasma Concentration (Tmax) of Qishe Pill in medial dosage
The time to maximum concentration
Time frame: 4 days after drug administration and blood sampling
The Time to Peak Plasma Concentration (Tmax) of Qishe Pill in high dosage
The time to maximum concentration
Time frame: 4 days after drug administration and blood sampling
Area under the Plasma Concentration versus Time Curve (AUC) of Qishe Pill in low dosage
The area under the plasma concentration-time curve (AUC) will be calculated using the linear trapezoidal rule.
Time frame: 4 days after drug administration and blood sampling
Area under the Plasma Concentration versus Time Curve (AUC) of Qishe Pill in medial dosage
The area under the plasma concentration-time curve (AUC) will be calculated using the linear trapezoidal rule.
Time frame: 4 days after drug administration and blood sampling
Area under the Plasma Concentration versus Time Curve (AUC) of Qishe Pill in high dosage
The area under the plasma concentration-time curve (AUC) will be calculated using the linear trapezoidal rule.
Time frame: 4 days after drug administration and blood sampling
The distribution volume (DF) of Qishe Pill in low dosage
The distribution volume (DF) will be calculated by Dose/AUC/ke. ke is the elimination rate constant.
Time frame: 4 days after drug administration and blood sampling
The distribution volume (DF) of Qishe Pill in medial dosage
The distribution volume (DF) will be calculated by Dose/AUC/ke. ke is the elimination rate constant.
Time frame: 4 days after drug administration and blood sampling
The distribution volume (DF) of Qishe Pill in high dosage
The distribution volume (DF) will be calculated by Dose/AUC/ke. ke is the elimination rate constant.
Time frame: 4 days after drug administration and blood sampling
Deep phenotyping with genomics and functional genomics approaches
3 ml blood samples for genomic variants analysis. The cytochrome P450 gene family, such as CYP1A1, CYP1A2, CYP2D6, CYP2C9, CYP2C19, CYP2E1, CYP3A4 and CYP3A5 , etc, will be chosen as the target objective.
Time frame: Dosing(0 hour)
Deep phenotyping with genomics and functional genomics approaches
3 ml blood samples for genomic variants analysis. The cytochrome P450 gene family, such as CYP1A1, CYP1A2, CYP2D6, CYP2C9, CYP2C19, CYP2E1, CYP3A4 and CYP3A5 , etc, will be chosen as the target objective.
Time frame: 2880 min after dosing
The Constitution in Chinese Medicine Questionnaire (CCMQ)
Two qualified traditional Chinese medical doctors licensed by the Chinese government determine the constitution according to CCMQ
Time frame: During screening in the recuitment
The Constitution in Chinese Medicine Questionnaire (CCMQ)
Two qualified traditional Chinese medical doctors licensed by the Chinese government determine the constitution according to CCMQ
Time frame: 2880 min after dosing
Laboratory measures and clinical assessment
These parameters including blood count, electrolytes, renal and liver function parameters, blood lipids, age, gender, history of smoking, blood pressure, weight (kg), and height (meters) will be obtained for all subjects.
Time frame: During screening in the recuitment
The record gives a start of Nov 2014, a primary completion of Dec 2015 and a completion of Jul 2016. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Nov 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Shanghai University of Traditional Chinese Medicine →